Tue.May 28, 2024

article thumbnail

Pharmacist-Provided Care for Common Conditions Could Increase Access, Save Money

Drug Topics

A recent study found that if community pharmacists were utilized to treat common conditions, it could result in significant cost-savings for the health care system.

211
211
article thumbnail

STAT+: Gene therapies for deafness dredge up an old question: Do deaf people want a ‘cure’?

STAT

When Yilai Shu was training to be an otolaryngologist in Shanghai, in the mid 2000s, he often met parents with congenitally deaf kids. “They always asked me, ‘Do you have any drugs to treat our kids?’ said Shu, who is hearing and a professor at Fudan University in China. “That’s what really inspired me to think about developing a drug.

143
143
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Slideshow: AI in Skin Cancer Awareness Creates New Opportunities for Care

Drug Topics

Research exploring the growing role of artificial intelligence (AI) in health care sheds a light on the potential of the technology to improve skin cancer detection and awareness among patients and health care professionals.

200
200
article thumbnail

STAT+: Merus drug, with immunotherapy, boosts tumor response in patients with head and neck cancer

STAT

Merus said Tuesday that the combination of its experimental drug petosemtamab with the checkpoint inhibitor Keytruda shrank tumors in 62% of patients with head and neck cancer, according to an interim analysis of an ongoing mid-stage clinical trial. The new efficacy results, derived from a larger number of patients, look similar to an initial disclosure made last week that triggered a 36% increase in Merus’ stock price.

137
137
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Emergency Visits in Canada Tripled After Legalization of Edible Cannabis

Drug Topics

Emergency department visits tripled by December 2022 compared with the pre-legalization period from January 2015 to September 2018.

155
155
article thumbnail

Takeda, amid restructuring campaign, plots 641 layoffs at two Massachusetts sites

Fierce Pharma

A recently announced $900 million restructuring drive is already making waves at Takeda, wi | From early July to March 2025, the Japanese drugmaker will cut 495 staffers at its Cambridge location and 146 in Lexington, Massachusetts. Takeda is the largest life sciences employer in the state.

134
134

More Trending

article thumbnail

Heat waves associated with increased risk of preterm birth in the U.S.

STAT

Heat waves are becoming more frequent and more intense, posing more of a health risk around the world. High temperatures can be deadly, and are especially dangerous for those with cardiovascular and chronic disease — but they begin affecting human lives even before birth. Several studies have identified an increased risk of preterm delivery and stillbirth after heat exposure around the world.

129
129
article thumbnail

Hospital orgs join cross-industry appeal for FTC to delay noncompete ban implementation

Fierce Healthcare

Hospital lobbies have signed onto a multi-sector letter of 230 industry associations and chambers of commerce urging the Federal Trade Commission to bump the effective date of its ban on employee n | The American Hospital Association and the Federation of American Hospitals are among 230 groups urging the regulator to put the final rule on hold pending legal challenges and "lack of Commission guidance on key pieces" of the ban.

Hospitals 128
article thumbnail

Breast Cancer Endocrine Therapy Nonpersistence, Nonadherence Associated With Socioeconomic and Behavioral Factors

Pharmacy Times

The authors note further research on technological monitoring methods can help health care providers better optimize patient care and improve nonadherence and nonpersistence.

article thumbnail

At Las Vegas conference, methadone clinics blast idea of doctors prescribing directly

STAT

LAS VEGAS — Mark Parrino, the longtime leader of the U.S. methadone clinic industry, kicked off his organization’s conference here last week with a simple message: Allowing addiction doctors to prescribe the medication directly to their patients is “not a good idea.”  It was a revealing warning both in timing and tone.

126
126
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

Data breach at pharma partner Cencora puts sensitive patient information at risk

Fierce Pharma

A data breach at drug distributor Cencora has left sensitive information vulnerable, with patients on medicines from a dozen drugmakers potentially affected. | The potentially compromised data included patient information such as names and addresses, Cencora disclosed in letters to patients who may have been affected.

125
125
article thumbnail

Semaglutide Shows Sustained Weight Loss Over 4 Years

Pharmacy Times

Added data from the SELECT trial helps to increase confidence in safety and efficacy of semaglutide, a glucagon-like peptide 1 medication.

132
132
article thumbnail

Opinion: Achieving telehealth equity for people with hearing loss

STAT

Gen Z has made captioning cool. Captions are now widely available in social media, entertainment channels, and web conferencing platforms, including YouTube, Hulu, and Zoom. Yet, there is one extremely important place where captions are not regularly available: telehealth visits. This disproportionately affects people with hearing loss. A friend of ours with hearing loss, whom we will call Cheryl, recently told us about her disappointing telehealth visit.

article thumbnail

While health AI legislation remains distant, Senate wants to appropriate funds, spur action in committees and agencies

Fierce Healthcare

While health AI legislation remains distant, Senate wants to appropriate funds, spur action in committees and agencies ebeavins Tue, 05/28/2024 - 14:35

124
124
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

STAT+: Airway disease drug from Insmed succeeds in one of the year’s most anticipated trials

STAT

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.   The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint.

Dosage 118
article thumbnail

AI is coming and regulators are getting prepared

pharmaphorum

The rise of AI is shaking up the healthcare industry. Learn how the MHRA is working to ensure the safe and effective use of AI in drugs and medical devices.

119
119
article thumbnail

STAT+: Japanese conglomerate to buy Calliditas Therapeutics, maker of a kidney disease drug

STAT

LONDON — Seeking to build up its pharma business, the Japanese conglomerate Asahi Kasei is moving to buy Swedish biotech Calliditas Therapeutics in a nearly $1.1 billion cash deal, the companies said Tuesday.   The firm’s offer of $19.68 per share amounts to an 83% premium versus Calliditas’ closing price on a Swedish exchange Monday.

115
115
article thumbnail

Japan's Asahi Kasei puts up $1.06B offer to buy out Tarpeyo maker Calliditas

Fierce Pharma

Bolstered by a full FDA approval for its primary immunoglobulin A nephropathy (IgAN) treatment Tarpeyo, Calliditas has earned the attention of Japanese chemical giant Asahi Kasei. | Asahi Kasei has made a cash offer to acquire Calliditas in a deal worth 11.16 billion Swedish crowns ($1.06 billion), the companies announced Tuesday. Asahi’s bid represents a 74% premium to Calliditas' prior closing price.

FDA 106
article thumbnail

STAT+: Pharmalittle: We’re reading about the Cencora data breach, a failed pandemic treaty, and more

STAT

Good morning, everyone, and welcome to another working week. We hope the weekend respite — which was extended on this side of the pond thanks to a holiday — was relaxing and invigorating. Now, though, the time has come to resume the usual routines of online meetings, phone calls, and what-not. After all, the world continues to spin, although it remains a bit wobbly where we are after losing a Pharmalot ancestor, which explains our recent disappearance.

Vaccines 104
article thumbnail

FDA Accepts Isatuximab for Priority Review for Treatment of Transplant-Ineligible Multiple Myeloma

Pharmacy Times

Isatuximab is used in combination with bortezomib, lenalidomide, and dexamethanose.

FDA 139
article thumbnail

Biotech’s most interesting fundraisings from the last week

STAT

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hi, biotech friends. As we gear up for ASCO, we cogitate on some interesting questions. For instance: Gene therapy carries great potential to cure certain forms of congenital deafness, but does the community actually want that?

FDA 101
article thumbnail

Bicycle Therapeutics secures $555M in private placement equity financing

Outsourcing Pharma

This funding round includes participation from both new and existing accredited investors, reinforcing confidence in Bicycle's innovative approach to precision-guided therapeutics.

98
article thumbnail

ASCO 2024: the latest in cancer research

STAT

The ASCO annual meeting is widely considered one of the largest and most prestigious cancer research conferences in the world. From May 31-June 4, more than 40,000 oncology professionals will gather in Chicago for an event featuring 200 professional sessions and the presentation of more than 5,000 abstracts. STAT will host a kickoff event May 31, featuring top experts in oncology, and will offer a live wrap-up broadcast on June 5.

FDA 99
article thumbnail

Trial readout sets up filings for Insmed bronchiectasis drug

pharmaphorum

Shares in Insmed double as phase 3 trial sets up filings for brensocatib, aiming to become the first approved drug for bronchiectasis

113
113
article thumbnail

Novartis rides IgAN trioka to 2 trial wins in rare kidney diseases

Fierce Pharma

Novartis is eyeing an FDA filing for a second drug in immunoglobulin A nephropathy (IgAN), as the Swiss pharma goes all-in on the rare autoimmune kidney disease from three different angles. | Novartis is eyeing an FDA filing for a second drug in immunoglobulin A nephropathy (IgAN), as the Swiss pharma goes all-in on the rare autoimmune kidney disease from three different angles.

FDA 96
article thumbnail

CG Oncology Reveals Promising Results from Phase II CORE-001 Clinical Trial for the Treatment of BCG-Unresponsive High-Risk Non-Muscle Invasive Bladder Cancer

Pharmaceutical Commerce

Results from the CORE-001 clinical trial are expected to be presented at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting.

105
105
article thumbnail

Hospital interoperability push moving from adoption to 'routine' use, ONC says

Fierce Healthcare

The proportion of hospitals meeting the Office of the National Coordinator for Health IT’s (ONC’s) bar for interoperability rose substantially from 2018 to 2023, though a focus on day-to-date data | Industrywide interoperability has jumped in the past half decade, but there's room for improvement among lower resourced hospitals and point-of-care use of external provider data, the Office of the National Coordinator for Health IT wrote in a recent data brief.

article thumbnail

ICYMI: Drug Topics May 2024 Issue

Drug Topics

Don’t miss out on the latest pharmacy insights in the Drug Topics May issue.

112
112
article thumbnail

Ex-Jazz, Sunesis exec Swisher takes over at NodThera

pharmaphorum

NLRP3-focused biotech NodThera has named former Jazz Pharma and Sunesis executive Dan Swisher as its new CEO.

115
115
article thumbnail

Exploring Therapeutic Alternatives to CDK4/6 Inhibitors in Metastatic Breast Cancer

Pharmacy Times

Heather Moore, BCOP, CPP, PharmD, discusses switching from CDK4/6 inhibitors to later lines of therapy, typically due to toxicities, to alleviate symptoms. She emphasizes the goal of finding a new therapy rather than abandoning treatment altogether, and notes that targeted therapy may be necessary in cases of disease progression.

81
article thumbnail

As weight loss booms, drugmakers look for an edge with oral options

PharmaVoice

Supply of GLP-1 medications falls well short of demand, and oral versions of the drugs loom over Eli Lilly and Novo Nordisk’s dominance.

98
article thumbnail

Proposed FDA Rule Could Limit Pharmacy Compounding

Pharmacy Times

Under the proposal, specific drugs would be prohibited

article thumbnail

In Depth Perspectives: Skin Care in the Digital Age, Tianeptine Misuse, And More

Drug Topics

Check out these top featured stories from Drug Topics in May 2024.

112
112
article thumbnail

FDA accepts Sanofi’s Sarclisa sBLA for priority review

Pharmaceutical Technology

The US FDA has accepted for priority review Sanofi's sBLA for Sarclisa regimen for transplant-ineligible newly diagnosed multiple myeloma.

FDA 94